The board of directors of Ambee Pharmaceuticals has recommended 30 per cent cash dividend for the year ended on June 30, 2017, said an official disclosure on Monday.
The final approval of dividend will come during the annual general meeting (AGM) scheduled to be held on December 21 in Dhaka.
The record date for entitlement of dividend is November 27 2017.
The company has also reported consolidated earnings per share (EPS) of Tk 3.02, consolidated net asset value (NAV) per share of Tk 25.24, and consolidated net operating cash flow per share (NOCFPS) of Tk 10.33 for the year ended on June 30, 2017 which was Tk. 3.41, Tk. 24.82, and Tk. 12.06 respectively for the 18 months period from January 01, 2015 to June 30, 2016.
In 2016, the company disbursed 26 per cent cash dividend.
There will be no price limit on the trading of the shares of the Company today (Monday) following its corporate declaration.
Each share of company, which was listed on the Dhaka bourse in 1986, closed at 409.90 on Sunday last the Dhaka Stock Exchange (DSE).
The company’s paid-up capital is Tk 24 million and authorised capital is Tk 25 million, while the total number of securities is 2.40 million.
Sponsor-directors own 5.26 per cent stake in the company while the institutional investors own 2.26 per cent, and the general public 22.38 per cent as of October 31, 2017, the DSE data shows.
